Molecular study reveals incomplete DNA methylation remodeling in transdifferentiated somatic cells, highlighting potential limits for regenerative cell replacement therapies.
The reprogramming of somatic cells into different lineages by transdifferentiation holds great promise for regenerative medicine and replacement therapies. However, a recent report by Radwan et al. (PNAS, 2024) finds that transdifferentiated cells fail to fully adopt the DNA methylation profiles of their new lineage. This has important implications regarding the viability of transdifferentiation as a strategy for cell replacement therapy.
No takes yet. Share an insight, caveat, or question.
Lord et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: